Susana Simões-Sousa1,2, Sara Granja1,2, Céline Pinheiro1,2,3,4, Daniela Fernandes1,2, Adhemar Longatto-Filho1,2,4,5, Ana Carolina Laus4, Cira Danielle Casado Alves6, J M Suárez-Peñaranda7, Mario Pérez-Sayáns8, Andre Lopes Carvalho4,6, Fernando C Schmitt9,10,11, Abel García-García8, Fatima Baltazar1,2. 1. a Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho , Braga , Portugal. 2. b ICVS/3B's-PT Government Associate Laboratory , Braga/Guimarães , Portugal. 3. c Barretos School of Health Sciences Dr. Paulo Prata - FACISB , Barretos , Sao Paulo , Brazil. 4. d Molecular Oncology Research Center, Barretos Cancer Hospital , Barretos , Sao Paulo , Brazil. 5. e Laboratory of Medical Investigation (LIM-14), Faculdade de Medicina da Universidade de , São Paulo , Brazil. 6. f Head and Neck Surgery Department , Barretos Cancer Hospital , Barretos , Sao Paulo , Brazil. 7. g Department of Pathology and Forensic Sciences , University Hospital and School of Medicine of Santiago de Compostela, Santiago de Compostela , A Coruña , Spain. 8. h Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry, Health Research Institute of Santiago (IDIS), Santiago de Compostela , A Coruña , Spain. 9. i IPATIMUP - Institute of Molecular Pathology and Immunology of University of Porto , Porto , Portugal. 10. j Medical Faculty of the University of Porto , Porto , Portugal. 11. k Department of Pathology and Medicine , Laboratoire National de Sante , Dudelange , Luxembourg.
Abstract
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common type of cancer. The majority of patients present advanced stage disease and has poor survival. Therefore, it is imperative to search for new biomarkers and new alternative and effective treatment options. Most cancer cells rely on aerobic glycolysis to generate energy and metabolic intermediates. This phenotype is a hallmark of cancer, characterized by an increase in glucose consumption and production of high amounts of lactate. Consequently, cancer cells need to up-regulate many proteins and enzymes related with the glycolytic metabolism. Thus, the aim of this study was to characterize metabolic phenotype of oral cavity cancers (OCC) by assessing the expression pattern of monocarboxylate transporters (MCTs) 1, 2 and 4 and other proteins related with the glycolytic phenotype. MATERIAL AND METHODS: We evaluated the immunohistochemical expression of MCT1, MCT4, CD147, GLUT1 and CAIX in 135 human samples of OCC and investigated the correlation with clinicopathological parameters and the possible association with prognosis. RESULTS: We observed that all proteins analyzed presented significantly higher plasma membrane expression in neoplastic compared to non-neoplastic samples. MCT4 was significantly associated with T-stage and advanced tumoral stage, while CD147 was significantly correlated with histologic differentiation. Interestingly, tumors expressing both MCT1 and MCT4 but negative for MCT2 were associated with shorter overall survival. CONCLUSION: Overexpression of MCT1/4, CD147, GLUT1 and CAIX, supports previous findings of metabolic reprograming in OCC, warranting future studies to explore the hyper-glycolytic phenotype of these tumors. Importantly, MCT expression revealed to have a prognostic value in OCC survival.
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common type of cancer. The majority of patients present advanced stage disease and has poor survival. Therefore, it is imperative to search for new biomarkers and new alternative and effective treatment options. Most cancer cells rely on aerobic glycolysis to generate energy and metabolic intermediates. This phenotype is a hallmark of cancer, characterized by an increase in glucose consumption and production of high amounts of lactate. Consequently, cancer cells need to up-regulate many proteins and enzymes related with the glycolytic metabolism. Thus, the aim of this study was to characterize metabolic phenotype of oral cavity cancers (OCC) by assessing the expression pattern of monocarboxylate transporters (MCTs) 1, 2 and 4 and other proteins related with the glycolytic phenotype. MATERIAL AND METHODS: We evaluated the immunohistochemical expression of MCT1, MCT4, CD147, GLUT1 and CAIX in 135 human samples of OCC and investigated the correlation with clinicopathological parameters and the possible association with prognosis. RESULTS: We observed that all proteins analyzed presented significantly higher plasma membrane expression in neoplastic compared to non-neoplastic samples. MCT4 was significantly associated with T-stage and advanced tumoral stage, while CD147 was significantly correlated with histologic differentiation. Interestingly, tumors expressing both MCT1 and MCT4 but negative for MCT2 were associated with shorter overall survival. CONCLUSION: Overexpression of MCT1/4, CD147, GLUT1 and CAIX, supports previous findings of metabolic reprograming in OCC, warranting future studies to explore the hyper-glycolytic phenotype of these tumors. Importantly, MCT expression revealed to have a prognostic value in OCC survival.
Entities:
Keywords:
aerobic glycolysis; head and neck cancer; lactate transport; monocarboxylate transporters
Authors: Kátia C Carvalho; Isabela W Cunha; Rafael M Rocha; Fernanda R Ayala; Mariana M Cajaíba; Maria D Begnami; Rafael S Vilela; Geise R Paiva; Rodrigo G Andrade; Fernando A Soares Journal: Clinics (Sao Paulo) Date: 2011 Impact factor: 2.365
Authors: Wenyue Sun; Yan Liu; Chad A Glazer; Chunbo Shao; Sheetal Bhan; Semra Demokan; Ming Zhao; Michelle A Rudek; Patrick K Ha; Joseph A Califano Journal: Clin Cancer Res Date: 2010-01-26 Impact factor: 12.531
Authors: Saskia E Rademakers; Jasper Lok; Albert J van der Kogel; Johan Bussink; Johannes H A M Kaanders Journal: BMC Cancer Date: 2011-05-12 Impact factor: 4.430
Authors: Simon J Park; Chase P Smith; Ryan R Wilbur; Charles P Cain; Sankeerth R Kallu; Srijan Valasapalli; Arpit Sahoo; Maheedhara R Guda; Andrew J Tsung; Kiran K Velpula Journal: Am J Cancer Res Date: 2018-10-01 Impact factor: 6.166
Authors: Ayşe Latif; Amy L Chadwick; Sarah J Kitson; Hannah J Gregson; Vanitha N Sivalingam; James Bolton; Rhona J McVey; Stephen A Roberts; Kay M Marshall; Kaye J Williams; Ian J Stratford; Emma J Crosbie Journal: BMC Clin Pathol Date: 2017-12-28
Authors: Alejandro I Lorenzo-Pouso; Mercedes Gallas-Torreira; Mario Pérez-Sayáns; Cintia M Chamorro-Petronacci; Oscar Alvarez-Calderon; Bahi Takkouche; Claudiu T Supuran; Abel García-García Journal: J Enzyme Inhib Med Chem Date: 2020-12 Impact factor: 5.051
Authors: Sara Bisetto; Diana Whitaker-Menezes; Nicole A Wilski; Madalina Tuluc; Joseph Curry; Tingting Zhan; Christopher M Snyder; Ubaldo E Martinez-Outschoorn; Nancy J Philp Journal: Front Oncol Date: 2018-08-28 Impact factor: 6.244
Authors: Mario Pérez Sayáns; Cintia Micaela Chamorro Petronacci; Alejandro Ismael Lorenzo Pouso; Elena Padín Iruegas; Andrés Blanco Carrión; José Manuel Suárez Peñaranda; Abel García García Journal: J Clin Med Date: 2019-11-07 Impact factor: 4.241